Biotechnology
InventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL Ventures
SHANGHAI, Sept. 28, 2020 /PRNewswire/ -- InventisBio, a clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, announced the recent completion of a$147 million series D financing which has attracted participation of many top biopharmaceutical ...
2020-09-28 05:00
3835
Radius Health & Menarini Group Provide Elacestrant Update
Target enrollment milestone reached in the Phase 3 EMERALD study Life cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy, Sept. 25, 2020 /PRNewswire/ -- -Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menari...
2020-09-25 18:15
6362
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by U.S. FDA
NEWARK, Del., Sept. 24, 2020 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced that its leading candidate, NR082 (rAAV2-ND4, NFS-01 project), was granted an orphan drug designation (ODD) by the U.S. FDA for the treatment of Leber's Hereditary O...
2020-09-25 10:37
2073
Cell Signaling Technology Named a Top Charitable Company in Massachusetts by the Boston Business Journal
DANVERS, Massachusetts, Sept. 24, 2020 /PRNewswire/ -- Cell Signaling Technology, Inc. (CST), a discovery technology company and leading provider of antibodies, kits, and services, was named by the Boston Business Journal (BBJ) for the 5th year in a row, as a 2020 top corporate charitable contrib...
2020-09-24 20:00
3405
KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development
SINGAPORE, Sept. 24, 2020 /PRNewswire/ -- KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has...
2020-09-24 17:12
1572
Macrogen, K-Quarantine System "Smart Mobile Lab" Exported to Indonesia
SEOUL, South Korea, Sept. 24, 2020 /PRNewswire/ -- Macrogen has established the
first "Smart Mobile Lab" in Korea and has supplied it toIndonesia as well.
2020-09-24 09:00
3725
SEMI-NBMC Invites White Paper Proposals for Funding of Human Monitoring Innovations
MILPITAS, California, Sept. 23, 2020 /PRNewswire/ -- SEMI Nano-Bio Materials Consortium (NBMC) today released a Request for Proposals (RFP) for innovations in ambulatory monitoring, wearable technologies for cognitive assessment, and innovative power sources for wearable monitors. Proposals are a...
2020-09-24 07:11
1900
ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital
SHENZHEN and SHANGHAI, Sept.23, 2020 /PRNewswire/ -- ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics today announced signing ofUS$10 million Series B Plus strategic financing. This round of financing wi...
2020-09-24 00:09
2063
Insilico releases Pandomics, AI-powered platform for Novel Therapeutic Target Discovery
A novel end-to-end AI-hypothesis generation engine that seamlessly interprets OMICS and text-based data for the discovery and analysis of novel therapeutic targets HONG KONG, Sept. 23, 2020 /PRNewswire/ -- Insilico Medicine announces the official release ofPandomics - a part of the Pharma.ai AI ...
2020-09-23 22:00
2864
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate
NEW BRUNSWICK, New Jersey, Sept. 23, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical ...
2020-09-23 19:25
4858
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
* Minoryx will receive an upfront and milestone payments of up to $78 million , as well as double digit royalties on annual net sales * Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-th...
2020-09-23 15:00
1423
Cosmo PR and HekaBio Announce Strategic Partnership and Investment in HekaBio
TOKYO, Sept. 22, 2020 /PRNewswire/ -- HekaBio K.K. (hereafter: HekaBio) and Cosmo Public Relations Corporation (hereafter:Cosmo) have announced that Cosmo has made an investment in HekaBio and that the companies have entered into a strategic partnership to increase awareness of and accessibility ...
2020-09-23 09:00
1848
Eurisotop Responds to Market Demand for Deuterated Chloroform
SACLAY, France, Sept. 22, 2020 /PRNewswire/ -- Eurisotop, a wholly owned subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), announced a capacity expansion of its deuterated chloroform production. Since its acquisition by CIL in 2001, Eurisotop has become a leading producer of deuterated NM...
2020-09-22 22:00
2279
Jennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market
RHEINBREITBACH and BONN, Germany, Sept. 22, 2020 /PRNewswire/ -- Jennewein Biotechnologie GmbH agreed to join forces with Chr. Hansen Holding A/S, a leading bioscience company based in Hoersholm/Denmark, to lead the global market for human milk oligosaccharides (HMOs). Chr. Hansen entered into an...
2020-09-22 21:36
2837
Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma
SYDNEY, Sept. 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with Dana-Farber Cancer Institute (DFCI) inthe United States, to investigate the use of...
2020-09-22 09:21
7591
Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply
INCHEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Pla...
2020-09-22 07:00
12612
PharmAbcine expands partnership with Samsung Biologics for PMC-403
DAEJEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular ...
2020-09-21 20:00
1580
Key Milestone: The first patient successfully dosed with the candidate drug SR419 for peripheral neuropathic pain
SHANGHAI, Sept. 21, 2020 /PRNewswire/ -- Shanghai SIMR Biotechnology Co., Ltd. (hereinafter referred to as "SIMR" or "Company") announced that, the clinical trial in patients with peripheral neuropathic pain has been initiated for the candidate drug SR419, and the first patient has been successfu...
2020-09-21 10:35
2172
Apis Partners leads US$15 million investment in Prenetics
* Investment will go into game-changing rapid COVID-19 test, highly accurate, results in 15-30 minutes, no lab required, low-cost. In discussions with Governments globally. * Enabling Travel Bubble: Prenetics, Cathay Pacific to launch pilot in October 2020 from HKG to LHR with The Commons Pro...
2020-09-18 08:00
5743
Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.
NANJING, China, Sept. 17, 2020 /PRNewswire/ -- On September 16th, 2020, GenScript ProBio and REMD Biotherapeutics Inc. (REMD) announced that REMD has licensed a bispecific antibody derived from the Single-domain antibody fused to Monoclonal Ab (SMAB) platform developed by GenScript ProBio. REMD i...
2020-09-17 22:00
2061
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 302 media titles]
2024-04-15 17:33
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 295 media titles]
2024-04-12 15:14
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
[Picked up by 276 media titles]
2024-04-11 11:00
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 275 media titles]
2024-04-15 08:00
Most Read
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
2024-04-11 11:00
6669
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
2024-04-12 15:14
6390
XCMG Machinery Launches Premium G2 Crane Brand
2024-04-12 14:39
6324
